GlassScriptPhysician profile
John G Gustafson
NPI 1992777437
$8,461.76
in general payments reported to CMS, 2019-2025
33 companies · $4,374 in 2025
The $4,374 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $334 · 2021: $719 · 2022: $549 · 2023: $574 · 2024: $938 · 2025: $4,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,162 · Travel and Lodging: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,161.98 |
| Travel and Lodging | $1,724.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,040.48 | 2020-2025 | Optis, Ultreon, Dragonfly Opstar |
| Boston Scientific Corporation | $638.55 | 2019-2025 | Avvigo Guidance System, Watchman Flx, General - Thrombectomy |
| Novartis Pharmaceuticals Corporation | $565.02 | 2019-2025 | |
| Abiomed | $435.34 | 2019-2024 | Impella |
| Inari Medical, INC. | $402.43 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.20 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $303.21 | 2019-2023 | Xarelto |
| Medtronic, INC. | $297.52 | 2022-2025 | Symplicity G3 |
| Cordis US Corp. | $224.20 | 2023-2025 | Mynxgrip, Radial 360 |
| Pfizer INC. | $222.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.51 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.18 | 2019-2025 | Jardiance |
| Stryker Corporation | $163.21 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $151.11 | 2019-2025 | Repatha |
| Shockwave Medical, INC | $149.74 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $143.35 | 2022-2025 | Opsynvi, Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $136.59 | 2019-2020 | |
| Edwards Lifesciences Corporation | $133.11 | 2024 | Sapien 3 Ultra Resilia |
| Penumbra, INC. | $121.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $83.87 | 2019-2023 | |
| Bridgebio Pharma, INC. | $72.74 | 2025 | Attruby |
| Gilead Sciences, INC. | $61.18 | 2019 | |
| Chiesi USA, INC. | $53.18 | 2024-2025 | Kengreal, Cleviprex |
| Bayer Healthcare Pharmaceuticals INC. | $50.99 | 2025 | |
| Teleflex LLC | $48.78 | 2019-2024 | Guideliner, Manta |
| Cardinal Health 200 LLC | $42.51 | 2019 | |
| Angiodynamics, INC. | $34.66 | 2024 | Alphavac |
| Imperative Care, INC | $30.50 | 2024 | Symphony Catheter |
| Regeneron Healthcare Solutions, INC. | $24.07 | 2019 | |
| Becton, Dickinson and Company | $22.21 | 2025 | Rotarexs 6 F X 135 Cm |
| W. L. Gore & Associates, INC. | $21.19 | 2024 | Gore Excluder Aaa Endoprosthesis |
| Bard Peripheral Vascular, INC. | $18.46 | 2024 | Venclose Maven Catheter |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gustafson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.